TG Therapeutics, Inc. (NASDAQ:TGTX) Receives $40.67 Average PT from Brokerages

TG Therapeutics, Inc. (NASDAQ:TGTX) has been given an average rating of “Moderate Buy” by the six research firms that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $40.67.

A number of equities analysts recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and set a $55.00 price target on shares of TG Therapeutics in a research note on Tuesday, March 4th. StockNews.com upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, March 4th.

TG Therapeutics Stock Performance

TG Therapeutics stock opened at $42.03 on Thursday. The company’s 50-day moving average price is $37.40 and its 200-day moving average price is $32.73. TG Therapeutics has a twelve month low of $12.93 and a twelve month high of $43.32. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. The company has a market cap of $6.67 billion, a PE ratio of -420.26 and a beta of 2.14.

TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share for the quarter, topping analysts’ consensus estimates of $0.08 by $0.07. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The firm had revenue of $108.19 million for the quarter, compared to the consensus estimate of $100.67 million. On average, equities research analysts forecast that TG Therapeutics will post 0.08 EPS for the current fiscal year.

Institutional Investors Weigh In On TG Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Bleakley Financial Group LLC purchased a new stake in TG Therapeutics in the 4th quarter valued at about $245,000. Castellan Group purchased a new stake in TG Therapeutics in the 4th quarter valued at about $8,539,000. Barclays PLC boosted its position in TG Therapeutics by 83.9% in the 3rd quarter. Barclays PLC now owns 347,057 shares of the biopharmaceutical company’s stock valued at $8,117,000 after buying an additional 158,323 shares during the period. JPMorgan Chase & Co. boosted its position in TG Therapeutics by 60.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 720,798 shares of the biopharmaceutical company’s stock valued at $16,859,000 after buying an additional 270,286 shares during the period. Finally, Stratos Wealth Advisors LLC purchased a new stake in TG Therapeutics in the 4th quarter valued at about $241,000. 58.58% of the stock is owned by hedge funds and other institutional investors.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.